2Suppliers
2Customers
3Debt Items
4Related Chains

Source-Backed Evidence Depth

PharmaCyte Biotech, Inc. (PMCB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

8Total relationships
2Distinct source URLs
5High confidence
0.810Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

PharmaCyte Biotech, Inc. Suppliers

TickerNameConfidenceEvidence
AUSTRIANOVA AUSTRIANOVA 92% Austrianova is responsible for acquiring all of the necessary raw materials used in this process, including the cellulose sulfate necessary for encapsulating the live cells, a process proprietary to …
QCLS Q/C Technologies, Inc. 72% Reciprocal relationship from QCLS graph: ension or failure. This would not be considered to be within the Company’s control. The estimated fair value of the Series F-1 Preferred Stock on the issuance…

PharmaCyte Biotech, Inc. Customers

TickerNameConfidenceEvidence
ASSOCIATED-TECHNOLOGIES ASSOCIATED-TECHNOLOGIES 62% s of future revenue. Any sales or operating results will likely generally depend on volume and timing of orders, which may not occur and on our ability to fulfill such orders, which we may not be abl…
SMALLER-REPORTING-COMPANY SMALLER-REPORTING-COMPANY 62% pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for whic…

PharmaCyte Biotech, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
PMCB-DEBT-11820 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-04-30.
PMCB-DEBT Debt stack $2.5M 90% Market cache reports total debt of $2.5M.
PMCB-DEBT-11819 Warrants outstanding: 33993104 90% xbrl warrant detail from xbrl 2025-07-31.

PharmaCyte Biotech, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for PharmaCyte Biotech, Inc..

PharmaCyte Biotech, Inc. Ownership

HolderNameConfidenceEvidence
PMCB-OWNER-CITADEL-ADVISORS-LLC CITADEL ADVISORS LLC 90% 13F overlay lists CITADEL ADVISORS LLC as top holder; 32 tracked holders.

PharmaCyte Biotech, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
QCLS Q/C Technologies, Inc. 100.00 1 ['supplier']
MIRA MIRA Pharmaceuticals, Inc. 50.00 2
INM InMed Pharmaceuticals Inc. 50.00 2
CNBX CNBX Pharmaceuticals Inc. 36.29 1 ['spend']
🔐
PMCB
Unlock PMCB Supply Chain Data
Verified relationships include:
AUSTRIANOVAAUSTRIANOVASupplier92%
QCLSQ/C Technologies, Inc.Supplier72%
ASSOCIATED-TECHNOLOGIESASSOCIATED-TECHNOLOGIESCustomer62%
SMALLER-REPORTING-COMPANYSMALLER-REPORTING-COMPANYCustomer62%
+4 more relationships locked
Subscribe — View plans →